Log in to save to my catalogue

AB1000 ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS. SPANISH NATIONAL REGISTRY IN A REAL-WORLD SETTIN...

AB1000 ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS. SPANISH NATIONAL REGISTRY IN A REAL-WORLD SETTIN...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3068592041

Publication information

Publisher

Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism

More information

Scope and Contents

Contents

Background:Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1), thus blocking the biological activity of type I IFNs. ANI was approved by Spanish authorities on June 1, 2023. Its use is indicated in adults with moderately to severely active autoantibody-positive systemic lupus erythematos...

Alternative Titles

Full title

AB1000 ANIFROLUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS. SPANISH NATIONAL REGISTRY IN A REAL-WORLD SETTING

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_3068592041

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3068592041

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/annrheumdis-2024-eular.2481

How to access this item